COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01854372
Recruitment Status : Withdrawn
First Posted : May 15, 2013
Last Update Posted : December 10, 2013
Information provided by (Responsible Party):
The University of Texas Health Science Center at San Antonio

Brief Summary:
To estimate the I-year progression-free survival probability in patients up to 70 years of age with previously untreated diffuse large B-celllymphoma (DLBCL), or with intermediate (Burkitt-like) lymphoma, whose tumor cells show MYC rearrangement, and who are treated with alternating cycles of Rituximab-HCV AD and Rituximab-Methotrexate-Cytarabine, in concert with optimal supportive treatment including Pegfilgrastim, prophylactic antimicrobials, and close clinical follow-up.

Condition or disease Intervention/treatment Phase
Newly Diagnosed Diffuse Large B-Cell Lymphoma Intermediate (Burkitt-Like) Lymphoma Drug: R-HCVAD and R-MC Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. A Phase 2, Multi-Center, Open Label Study (CTRC# 11-53)
Study Start Date : June 2013
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Arm Intervention/treatment
Experimental: R-HCVAD and R-MC Chemotherapy

R-HCVAD - Rituximab (375 mg/m2), Cyclophosphamide (300 mg/m2), Mesna (600 mg/m2), Doxorubicin (50 mg/m2), Vincristine (2 mg total), Dexamethasone (40 mg total), Methotrexate (12 mg), Cytarabine (100mg).

R-MC -Rituximab (375 mg/m2),Methotrexate (200 mg/m2 - 800mg/m2), Cytarabine (3000mg/m2), Leucovorin (15mg - 50mg).

Drug: R-HCVAD and R-MC

Primary Outcome Measures :
  1. Progression free survival verified by PET scan. [ Time Frame: 6 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diffuse large B-cell lymphoma or intermediate ("Burkitt-like") lymphoma, newly diagnosed from an excisional biopsy or from a large core biopsy with sufficient diagnostic material to perform genetic testing for MYC-R.
  2. Positivity for MYC-R by Fluorescent in-situ Hybridization (FISH) or by classical cytogenetics.
  3. No prior lymphoma treatment, with one exception: One cycle of R-CHOP regimen is permitted (consisting of one single dose each of Rituximab, of cyclophosphamide, of doxorubicine, and of vincristine, as well as up to 5 doses of Prednisone when part of chemotherapy).
  4. No prior radiation therapy is permitted
  5. Age ≥ 18 years to 70 years of age
  6. CT imaging of neck, chest, abdomen and pelvis within 28 days prior to registration. Any additional imaging used to assess extent of disease must also have been done within 28 days prior to registration
  7. Bidimensionally measurable disease by imaging within 28 days prior to registration
  8. Adequate bone marrow biopsy, and aspiration performed for staging within 28 days before registration, and before start of any treatment
  9. Indication for primary treatment with systemic multiagent chemotherapy
  10. Creatinine ≤ 2.0 mg/dL and estimated (Cockroft-Gault) creatinine clearance> 50 ml/min within 7 days prior to registration
  11. Cardiac ejection fraction of ≥ 50% by MUGA scan or by 2-D echocardiogram , as well as EKG without significant abnormality within 28 days prior to registration
  12. Performance status of 0, of 1, or of 2 (ECOG scale)
  13. Patient willing to have, and to maintain, a central venous line throughout the treatment phase (either PICC line, or double lumen tunnelled catheter, or double lumen subcutaneous venous port system)
  14. Willing and logistically able to be followed as outpatient at least twice weekly, during the treatment phase.
  15. Signed informed consent to accept transfusion of blood products as medically indicated
  16. Signed informed consent to participate in this trial

Exclusion Criteria:

  1. Age > 70 years
  2. Leukemic presentation, or no evidence of disease by imaging
  3. Unwilling to be screened for HIV. HIV positive patients must receive combined antiretroviral treatment while on study. They are excluded from participation unless they show a CD4 count >250/uL and a viral load < 50 within 28 days of registration.
  4. Hepatic involvement and total serum bilirubin ≥ 5 mg/dL within 7 days prior to registration, or total serum bilirubin ≥ 1.6 mg/ dL without hepatic involvement within 7 days prior to registration
  5. Patients with bone marrow involvement and either ANC < 1000/uLor Platelets < 50,000/uL, within 7 days before registration
  6. Patients without bone marrow involvement by lymphoma, and either ANC < 1500/uL or Platelets < 100,000/uL within 7 days before registration
  7. Patients with myelodysplastic syndrome, with sickle cell disease, or with transfusion dependence for over 6 months antedating the diagnosis oflymphoma.
  8. Known hypersensitivity to E. coli derived proteins
  9. Patients at risk of reactivation of hepatitis B who are unwilling to be treated with appropriate antivirals as medically indicated.
  10. Pregnant or nursing women, or any patient with reproductive potential and unwilling to use effective contraceptive method from study start to one year after the last dose of protocol therapy. Adequate contraception is defined as hormonal birth control, intrauterine device, double barrier method, or total abstinence.
  11. Additional or prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for ~ 5 years
  12. Unwilling to receive transfusions of blood products as medically indicated
Layout table for additonal information
Responsible Party: The University of Texas Health Science Center at San Antonio Identifier: NCT01854372    
Other Study ID Numbers: CTRC 11-53
First Posted: May 15, 2013    Key Record Dates
Last Update Posted: December 10, 2013
Last Verified: December 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin